Key Financial Performance

Standalone Results:

  • Income from Operations: ₹1,885.743 million (FY26) vs ₹1,815.873 million (FY25) – 3.85% growth
  • Profit After Tax: ₹323.996 million (FY26) vs ₹311.569 million (FY25) – 3.99% growth
  • Earnings Per Share: ₹9.57 (Basic & Diluted) vs ₹19.37 (FY25), decrease due to increased share capital

Consolidated Results:

  • Revenue from Operations: ₹23,547.49 lakhs (FY26) vs ₹19,831.85 lakhs (FY25) – 18.73% growth
  • Net Profit After Tax: ₹3,016.64 lakhs (FY26) vs ₹2,670.06 lakhs (FY25)
  • Export Sales: ₹13,281.46 lakhs (70% of revenue) showing strong international presence

Operational Highlights

  • New Manufacturing Facility: Commissioned EU-GMP/USFDA compliant greenfield facility at Pen, Maharashtra with over 14 acres campus and 18,000+ sq. mtr. built-up area for sterile injectables and ophthalmic preparations
  • Ethiopia Facility: Kilitch Estro Biotech PLC achieved over 100% revenue growth during FY26
  • Product Performance: General Injectable segment showed 28.72% growth to ₹751.331 million

Corporate Actions & Capital Structure

  • Right Issue: Issued 1,398,463 right equity shares at ₹357 per share in ratio of 2:23 to existing shareholders
  • Bonus Issue: Completed 1:1 bonus issue, issuing 17,480,782 fully paid-up bonus equity shares
  • Paid-up Capital: Increased from ₹160.823 million to ₹349.616 million during the year
  • Authorised Capital: Increased from ₹250 million to ₹400 million

Financial Position & Ratios

  • Trade Receivables: ₹12,017.71 lakhs with provision for expected credit losses of ₹1,373.79 lakhs
  • Borrowings: Increased to ₹8,870.90 lakhs (FY26) from ₹4,942.40 lakhs (FY25)
  • Cash Equivalents: ₹1,577.40 lakhs (FY26) vs ₹980.05 lakhs (FY25)
  • Key Ratios: Return on Net Worth 9.41%, Debt-Equity Ratio 0.27, Operating Profit Margin 52.87%

Subsidiaries & Investments

  • Monarchy Healthserve Private Limited: Wholly-owned subsidiary with no business operations
  • Kilitch Estro Biotech PLC (Ethiopia): 67% owned subsidiary, revenue ₹475.654 million, net loss ₹20.184 million
  • Arham Neeta Realties LLP: Investment with capital of ₹2,128.54 lakhs, share of loss ₹0.56 lakhs

AGM Details & Corporate Governance

The 34th Annual General Meeting is scheduled for August 27, 2026, at 9:00 AM IST through Video Conferencing. Key agenda items include:

  • Adoption of audited standalone and consolidated financial statements
  • Re-appointment of Mr. Mukund P. Mehta as director
  • Approval of performance-linked incentive totaling ₹200 lakhs for executive directors
  • Ratification of Cost Auditor remuneration

No dividend recommended for FY 2025-26 as profits were retained for growth initiatives. Record date set for August 20-27, 2026.

Contingent Liabilities & Provisions

  • Property Tax demand of ₹53.20 lakhs for FY 2019-20, disputed and pending in Supreme Court
  • CESS demand of ₹22.85 lakhs for FY 1999-2000 & 2000-01, disputed and pending in Supreme Court
  • Provision for expected credit loss of ₹352.92 lakhs recognized in FY26

Employee Benefits & CSR

  • Total permanent employees: 236, with 45% women employees
  • Gratuity obligation increased to ₹121.79 lakhs (FY26) from ₹68.67 lakhs (FY25)
  • CSR Expenditure: ₹55.95 lakhs on children healthcare, education, nutrition, and community development